Details

Autor(en) / Beteiligte

• Stertman, Linda
• Palm, Anna-Karin E
• Zarnegar, Behdad
• Carow, Berit
• Lunderius Andersson, Carolina
• Magnusson, Sofia E
• Carnrot, Cecilia
• Shinde, Vivek
• Smith, Gale
• Glenn, Gregory
• Fries, Louis
• Lövgren Bengtsson, Karin

Titel

The Matrix-M™ adjuvant: A critical component of vaccines for the 21 st century

Ist Teil von

• Human vaccines & immunotherapeutics, 2023-12, Vol.19 (1), p.2189885

Ort / Verlag

United States

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Matrix-M™ adjuvant is a key component of several novel vaccine candidates. The Matrix-M adjuvant consists of two distinct fractions of saponins purified from the Molina tree, combined with cholesterol and phospholipids to form 40-nm open cage-like nanoparticles, achieving potent adjuvanticity with a favorable safety profile. Matrix-M induces early activation of innate immune cells at the injection site and in the draining lymph nodes. This translates into improved magnitude and quality of the antibody response to the antigen, broadened epitope recognition, and the induction of a Th1-dominant immune response. Matrix-M-adjuvanted vaccines have a favorable safety profile and are well tolerated in clinical trials. In this review, we discuss the latest findings on the mechanisms of action, efficacy, and safety of Matrix-M adjuvant and other saponin-based adjuvants, with a focus on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subunit vaccine candidate NVX-CoV2373 developed to prevent coronavirus disease 2019 (COVID-19).